Teva (NYSE: TEVA) Exec VP exercises options, sells 115,468 shares at $28.68

Rhea-AI Filing Summary

Teva Pharmaceutical Industries executive exercises options and sells shares

On December 9, 2025, a Teva Pharmaceutical Industries Ltd. executive, identified as an officer serving as Exec. VP, European Commercial, reported multiple equity transactions. The executive exercised 100,457 stock options at an exercise price of $18.61 per share and another 15,011 stock options at an exercise price of $16.99 per share, receiving the same number of Teva ordinary shares. On the same day, the executive sold 115,468 ordinary shares at a weighted average price of $28.6757 per share, leaving 48,384 ordinary shares beneficially owned directly after the transactions. The filing notes that Teva ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniell Richard

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV L3 6944020

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, European Commercial

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	12/09/2025		M		100,457	A	$18.61	148,841	D
Ordinary Shares(1)	12/09/2025		M		15,011	A	$16.99	163,852	D
Ordinary Shares(1)	12/09/2025		S		115,468	D	$28.6757(2)	48,384	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$18.61	12/09/2025		M			100,457	(3)	02/09/2028	Ordinary Shares(1)	100,457	$0	0	D
Stock Options (right to buy)	$16.99	12/09/2025		M			15,011	(4)	09/18/2027	Ordinary Shares(1)	15,011	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.635 to $28.765, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

3. Stock options were granted on February 9, 2018, with 33,485 vested on each of February 9, 2020 and February 9, 2021, and 33,487 vested on February 9, 2022.

4. Stock options were granted on September 18, 2017, with 7,505 vested on September 18, 2018, and 7,506 vested on September 18, 2019.

	/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What type of insider filing did TEVA submit in this document?

This document is a Form 4, which reports changes in the beneficial ownership of Teva Pharmaceutical Industries Ltd. equity securities by one of its officers.

Who is the insider involved in this TEVA Form 4 and what is their role?

The insider is an officer of Teva Pharmaceutical Industries Ltd., serving as Exec. VP, European Commercial, and is a reporting person for these equity transactions.

What stock options did the TEVA executive exercise on December 9, 2025?

On December 9, 2025, the executive exercised 100,457 stock options with an exercise price of $18.61 and 15,011 stock options with an exercise price of $16.99, receiving the same number of ordinary shares.

How many TEVA shares did the insider sell and at what price?

The insider sold 115,468 ordinary shares at a weighted average price of $28.6757 per share, with individual sale prices ranging from $28.635 to $28.765.

How many TEVA shares does the insider own after these transactions?

Following the reported transactions, the insider beneficially owns 48,384 ordinary shares of Teva Pharmaceutical Industries Ltd. directly.

What is the relationship between TEVA ordinary shares and American Depositary Shares (ADS)?

Each American Depositary Share of Teva Pharmaceutical Industries Ltd. currently represents one ordinary share, according to the disclosure.

Were there any TEVA stock options remaining after the reported exercises?

After exercising the options described, the number of derivative securities (stock options) beneficially owned is reported as 0 for each of the two option grants.